Global Expansion And Clinical Readouts Will Unlock New Markets

Published
29 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$205.50
26.9% undervalued intrinsic discount
14 Aug
US$150.27
Loading
1Y
-24.4%
7D
9.3%

Author's Valuation

US$205.5

26.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 15%

Shared on30 Apr 25
Fair value Decreased 0.037%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 0.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 1.31%

AnalystConsensusTarget has decreased revenue growth from 50.5% to 41.6%, increased profit margin from 47.7% to 54.0% and decreased future PE multiple from 21.4x to 16.8x.